Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
FDA Gives Green Light to OK-101 Trial for NCP Treatment
Okyo Pharma’s first investigational new drug (IND) application for OK-101 has been cleared by the U.S. Food and Drug Administration (FDA), marking a pivotal moment in the development of potential therapies for neuropathic corneal pain. Initially proposed as an open-label…
New Features at ESCRS Winter Meeting in Frankfurt
The European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting in Frankfurt at Congress Centre Messe Frankfurt, scheduled for February 15-18, 2024, promises an array of new sessions and activities aimed at fostering collaboration, learning, and networking within the…
Glaukos Secures FDA Approval for iDose TR
Glaukos has received FDA approval for iDose TR (travoprost intracameral implant 75 mcg), a groundbreaking prostaglandin analog intracameral implant designed to reduce intraocular pressure (IOP) in individuals with ocular hypertension or open-angle glaucoma. The iDose TR procedure, sanctioned for a…
Eyenovia’s Mydcombi Approved by the FDA
Eyenovia Inc. announced that the FDA has approved Mydcombi, a groundbreaking ophthalmic spray that induces mydriasis for diagnostic procedures and short-term pupil dilation. This marks the first approved, fixed-dose combination of tropicamide and phenylephrine in the United States and also…
Top 10 Trends to Watch in Ophthalmology
The field of ophthalmology is constantly evolving with new technologies and treatments emerging every year. In the next decade, we can expect even more advancements that will revolutionize the way we approach eye care. Here are the top 10 eye…
Japanese Astellas Pharma Acquires Iveric Bio for $5.9 Billion
Astellas Pharma, a Japanese drugmaker, announced the acquisition of Iveric Bio, a pharmaceutical company that is currently in the late stages of developing a geographic atrophy drug. The acquisition is valued at $5.9 billion, and under the terms of the…
Ophthalmology’s Leap with Emerging Technologies
In a recent survey conducted on LinkedIn by the Ophthalmology Breaking News (OBN), ophthalmology professionals were asked to identify the emerging technology they believed held the most promise for improving surgical outcomes in their field. The results shed light on…
New FDA Warning: Hearing Impairment Risks in TEPEZZA
The US Food and Drug Administration (FDA) has taken action to update the warning label on Horizon Pharmaceutical’s TEPEZZA, a drug used to treat thyroid eye disease (TED), to include the risk of hearing impairment or loss. The recent addition…
Edenlux’s Otus Personal EYE-Trainer | OBN
The Otus personal eye-trainer, developed by Edenlux, has launched a campaign through Indiegogo. The device uses training called Vision Therapy to relieve the stress of the eyes. Vision Therapy is an exercise that repeats the contraction and relaxation of the…
FDA Approves Vuity for Twice-Daily Dosing in Presbyopia
AbbVie, the parent company of Allergan, has announced that the FDA has granted approval for the use of Vuity (pilocarpine HCl ophthalmic solution) 1.25% twice a day in adults suffering from presbyopia. The second dose, consisting of an additional drop…